OBJECTIVE: To evaluate the effects on signs and symptoms of a coexisting @entity5902 in @entity1 treated with oral @entity5203 for @entity565 . METHODS: Twelve @entity1 with @entity5902 and @entity565 were enrolled in this pilot study. Topical eyedrops or any systemic treatment was discontinued for at least 7 days before montelukast treatment. @entity1 were asked to grade their ocular discomfort daily. The following signs and symptoms were also recorded and graded through medical examination at baseline,after 15 days of treatment, and 15 days after treatment discontinuation: physician-evaluated @entity1829 , @entity450 , secretion, and chemosis; and @entity1 -evaluated itching, burning, @entity937 , @entity3917 , foreign body sensation, secretion, and redness. Peak expiratory flow rate at 8 AM was also recorded. Samples were collected at the same time points for enzyme-linked immunosorbent assay measurement of @entity8285 in tears and leukotriene E4 in urine. RESULTS: Eight of the 10 @entity1 evaluated reported a reduction in symptoms at the end of treatment. Montelukast treatment significantly decreased physician-rated @entity450 , secretion, and chemosis as well as @entity1 -rated burning, @entity937 , @entity3917 , secretion, and redness. Effects persisted 15 days after discontinuation of treatment. Clinical changes were associated with a significant increase in @entity8285 in tears and a significant decrease in @entity11130 in urine after 15 days of treatment. CONCLUSION: The significant and persistent reduction of ocular signs and symptoms in @entity748 @entity1 with @entity5902 treated for 15 days with @entity5203 strongly suggests the need for double-masked placebo-controlled trials to confirm the potential of this new treatment in @entity5902 .

Montelukast, a leukotriene receptor antagonist, in XXXX associated with @entity565 .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient'] @entity8285 :: ('MESH:D007975', 'Chemical') :: ['leukotriene B4'] @entity748 :: ('MESH:D013224', 'Disease') :: ['asthmatic'] @entity937 :: ('MESH:D012167', 'Disease') :: ['tearing'] @entity11130 :: ('MESH:D017999', 'Chemical') :: ['leukotriene E4'] @entity565 :: ('MESH:D001249', 'Disease') :: ['asthma'] @entity450 :: ('MESH:D006940', 'Disease') :: ['hyperemia'] @entity1829 :: ('MESH:D010211', 'Disease') :: ['tarsal and bulbar papillae'] @entity5902 :: ('MESH:D003233', 'Disease') :: ['vernal keratoconjunctivitis'] @entity3917 :: ('MESH:D020795', 'Disease') :: ['photophobia'] @entity5203 :: ('MESH:C093875', 'Chemical') :: ['montelukast', 'montelukast sodium']
@entity5902 :: (MESH:D003233,Disease) :: ['vernal keratoconjunctivitis']
